Drug
Rapamycin (sirolimus)
Rapamycin (sirolimus) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Not yet recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed250%
not_yet_recruiting250%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_1
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
NCT07735546
not_yet_recruitingphase_1
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
NCT07735533
completedphase_1
Rapamycin With Grapefruit Juice for Advanced Malignancies
NCT00375245
completedphase_2
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
NCT00457808
Clinical Trials (4)
Showing 4 of 4 trials
NCT07735546Phase 1
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
NCT07735533Phase 1
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
NCT00375245Phase 1
Rapamycin With Grapefruit Juice for Advanced Malignancies
NCT00457808Phase 2
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4